Home
Charts
Search
Watchlist
Products
All IPOs
₹100 - 106
Himalaya Nutravedics India Ltd
PharmaceuticalsIPOSME
₹100 - 106
Founded in 2022, Himalaya Nutravedics India Limited manufactures classical and proprietary Ayurvedic formulations alongside nutraceutical supplements out of an integrated facility in Hyderabad, distributing through a doctor-led prescription model and contract manufacturing partnerships. The company pairs traditional herbal extraction with modern capsule and tablet lines to supply healthcare practitioners across India while filling plant capacity through external corporate formulation orders.
Lot1,200Min Invest₹2,54,400Face Value₹10Issue Size₹27 CrFresh Issue₹27 Cr
Timeline
22 Sept
Bidding opens
24 Sept
Bidding closes
25 Sept
Allotment
28 Sept
Refund & demat credit
29 Sept
Listing
Subscription
Subscription opens 22 Sept
Reports
Offer Details
Terms
Issue Size₹27 Cr
Fresh Issue₹27 Cr
Face Value₹10
Lot Size1,200 shares
ReservationQIB 49.9% · NII 15.02% · RETAIL 35.08%
Application Sizes
Retail₹2,54,4001-1 lots
sNII₹2,54,400from 2 lots
bNII₹10,17,600from 8 lots
Managers & Registrar
Lead ManagerNirbhay Capital Services Pvt Ltd
RegistrarKFin Technologies Ltd
Ownership & Proceeds
Shareholding
CategoryPre IPOPost IPOPromoter Group95.14%68.14%Public4.86%31.86%
Objects of the Issue
- Funding Working Capital Requirements
- Investment in Branding, Digital Marketing and Sales Expansion
- General Corporate Purposes
Anchor Book
Bid Date21-Sep-202630-day lock-in24-Oct-202690-day lock-in23-Dec-2026
Financials
Profit & Loss
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| RevenueCr | 2 | 14 | 21 | 43 |
| Operating ProfitCr | 0 | 1 | 3 | 8 |
| OPM% | 13.7 | 7.0 | 14.2 | 18.8 |
| PBTCr | 0 | 1 | 2 | 7 |
| PATCr | 0 | 1 | 2 | 7 |
| EPS | 0 | 6 | 25 | 18 |
Balance Sheet
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity CapitalCr | 1 | 1 | 4 | 6 |
| ReservesCr | 0 | 1 | 3 | 10 |
| BorrowingsCr | 1 | 3 | 2 | 5 |
| Total AssetsCr | 3 | 6 | 11 | 24 |
Cash Flow
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Operating Cash FlowCr | -1 | -1 | -1 | -4 |
| Investing Cash FlowCr | -1 | -1 | 0 | 0 |
| Financing Cash FlowCr | 1 | 2 | 1 | 5 |
| Net Cash FlowCr | -1 | 0 | 0 | 1 |
Strengths & Risks
Strengths · as stated in the DRHP
- Experienced Promoters and Management Team.
- End to end execution capabilities.
- Long term Relationship with the Clients.
- Quality Assurance & Control.
Strategies · as stated in the DRHP
- Expansion of our business of branded products on a Pan-India Basis.
- Expansion and Diversification of Product Portfolio.
- Increasing Contribution from Higher-Margin Sales.
- Manufacturing and Operational Strengthening.
- Entry into Export Markets.
- Digital outreach and market development strategy.
Risks · as stated in the DRHP
- The company may be unable to sufficiently obtain, maintain, protect, or enforce its intellectual property and other proprietary rights.
- The company derives a significant portion of its revenue from the sale of products in the Ayurvedic products which constituted 94.57%, 92.09% and 79.27% of the company's revenue from operations for the Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for these products could have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company is dependent on and derives a substantial portion of its revenue from certain key customers. Revenue generated from the company's top 10 customers accounted for 81.24%, 86.97%, and 84.19%, of its revenue from operations during the Fiscals 2026, 2025 and 2024, respectively. Loss of relationship with any of these customers or delays or reductions in their orders may have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The company has historically derived, and may continue to derives, a significant portion of its supply from top 10 Suppliers.
- The company profitability may be adversely affected upon the expiry of tax benefits available under Section 80-IAC of the Income Tax Act, 1961, as applicable under the existing tax regime, and under Section 140 of the Income Tax Act, 2025, upon such new tax regime becoming effective.
- The company operates out of a single Manufacturing Facility, located at Hyderabad, Telangana which exposes its operations to potential geographical concentration risks arising from local and regional factors which may adversely affect the company operations and in turn its business, results of operations and cash flows.